Certificate of Analysis
Independent analysis of this lot by Kovera Labs (HPLC-UV).
- Purity
- 99.43%
- Lot
- ML-260929
- Tested Most recent
- Sep 2026
LP2-T Peptide
In Stock- CAS
- 2023788-19-2
- Molecular weight
- ~4813 g/mol
- Form
- Lyophilized powder
- Purity (HPLC)
- 99.43% HPLC-UV
- Storage
- -20°C or colder
- Lot / COA
- Free shippingOn every order
- Free 2nd Day AirOn orders $200+
Research Use Only
For laboratory research use only. Not for human consumption. All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Specifications
- CAS
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Molecular weight
- ~4813 g/mol
- Form
- Lyophilized powder
- Purity (HPLC)
- 99.43% HPLC-UV
- Storage
- -20°C or colder
- Lot / COA
- PubChem CID
- 156588324
Certificate of Analysis
Independent analysis of this lot by Kovera Labs (HPLC-UV).
- Purity
- 99.43%
- Lot
- ML-260929
- Tested Most recent
- Sep 2026
LP2-T Peptide Overview
LP2-T is a synthetic peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Its dual-receptor profile allows researchers to examine interactions between two related incretin signaling systems within a single experimental model. LP2-T is the Medicina Labs catalog designation for this material; its identity is defined by the CAS registry number, molecular formula, and PubChem identifier listed in the structure section below.
Studies involving LP2-T have focused on receptor pharmacology, intracellular signaling, endocrine regulation, metabolic pathway dynamics, and potential synergistic effects produced by simultaneous GIPR and GLP-1R activation.
History
The development of LP2-T followed advances in selective GLP-1 receptor agonist research. Investigators hypothesized that simultaneously engaging GIP and GLP-1 signaling could produce a distinct integrated biological response compared with targeting either pathway independently.
Researchers at Eli Lilly developed a 39-amino-acid synthetic peptide based in part on the GIP sequence and engineered it to activate both GIP and GLP-1 receptors while incorporating structural modifications that extend molecular activity. The compound was described in detail by Coskun and colleagues in 2018.
LP2-T Structure
CAS #: 2023788-19-2
Molecular Formula: C225H348N48O68
Molecular Weight: ~4813 g/mol
PubChem ID: 156588324
Research Findings
LP2-T has been investigated across endocrine, receptor, metabolic, and intracellular signaling models. Of particular research interest is the interaction between GIPR and GLP-1R signaling and the potential for coordinated activity across the two receptor systems.
Key Areas of Research:
- Dual Receptor: GIPR and GLP-1R activation
- Endocrine: Integrated incretin signaling
- Molecular: Receptor crosstalk and downstream cascades
- Systemic: Glucose, lipid, and energy-regulation pathways
Together, these findings make LP2-T a research platform for examining dual-receptor pharmacology and the biological consequences of coordinated GIP and GLP-1 pathway activation.
Specifications, Testing & Storage
LP2-T is supplied in 10mg and 30mg sizes as lyophilized (freeze-dried) powder in sealed glass vials, each labeled with the product name, lot number, quantity, and storage instructions.
Purity is measured by HPLC (High-Performance Liquid Chromatography), and a Certificate of Analysis is available for every batch. Lyophilized material should be stored at -20°C or colder upon arrival.
LP2-T is supplied strictly for laboratory research use only and is not intended for human or animal use.
Our Process
Precision Lyophilization
Each batch is freeze-dried and sealed for stability until reconstitution.
Verified Purity
Every batch is third-party tested with HPLC and mass spectrometry.
Careful Fulfillment
Orders ship within 24 hours from our U.S. facility.